TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03595852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: Cefazolin will be given to patients in the experimental arm prophylactically prior to surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: IV normal saline will be given to patients 30-60 minutes prior to incision
Study: NCT01153880

Intervention type: DRUG
Intervention: Retapamulin
Description: Prescription sales claim of retapamulin

Intervention type: DRUG
Intervention: Retapamulin
Description: Prescription sales claim of retapamulin

Intervention type: DRUG
Intervention: Retapamulin
Description: Prescription sales claim of retapamulin

Intervention type: DRUG
Intervention: Retapamulin
Description: Prescription sales claim of retapamulin

Intervention type: DRUG
Intervention: Retapamulin
Description: Prescription sales claim of retapamulin

Intervention type: DRUG
Intervention: Retapamulin
Description: Prescription sales claim of retapamulin

Intervention type: DRUG
Intervention: Co-prescription of retapamulin and topical mupirocin
Description: Same day prescription sales claims for retapamulin and topical mupirocin

Intervention type: DRUG
Intervention: Co-prescription of retapamulin and topical mupirocin
Description: Same day prescription sales claims for retapamulin and topical mupirocin

Intervention type: DRUG
Intervention: Co-prescription of retapamulin and topical mupirocin
Description: Same day prescription sales claims for retapamulin and topical mupirocin

Intervention type: DRUG
Intervention: Co-prescription of retapamulin and topical mupirocin
Description: Same day prescription sales claims for retapamulin and topical mupirocin

Intervention type: DRUG
Intervention: Co-prescription of retapamulin and topical mupirocin
Description: Same day prescription sales claims for retapamulin and topical mupirocin

Intervention type: DRUG
Intervention: Co-prescription of retapamulin and topical mupirocin
Description: Same day prescription sales claims for retapamulin and topical mupirocin
Study: NCT04413812

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FREEBASE exercise programme
Description: The exercise programme will be initialized 1-10 months following bariatric surgery and last for 3 months. The programme will be mainly delivered in two groups consisting of 10-12 subjects each and will be held in the facilities of a fitness studio and remotely at home. The programme consists of 24 units (two per week, the lesson in the fitness studio lasting for 75 minutes and the remote lesson lasting for 45 minutes.This is due to the COVID-19-related social distancing restrictions. The intervention combines the following elements: a) exercise training in a group, b) interactive workshops on basic knowledge of training sciences and techniques of behavior change and c) an individual exercise counselling session.~The programme will be medically supervised and the content will be taught and instructed by members of the research team qualified in exercise science and sports physiology.
Study: NCT03647969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240mg Flatdose i.v. d1 over 30 minutes every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240mg Flatdose i.v. d1 over 30 minutes every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240mg Flatdose i.v. d1 over 30 minutes every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1mg/kg i.v. d1 over 30 minutes every 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1mg/kg i.v. d1 over 30 minutes every 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX
Description: Oxaliplatin at a dose of 85 mg/m² iv over two hours (day 1), Leucovorin at a dose of 400 mg/m2 iv over two hours (day 1), Fluorouracil at a dose of 400 mg/m² iv bolus (day 1), and Fluorouracil at a dose of 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX
Description: Oxaliplatin at a dose of 85 mg/m² iv over two hours (day 1), Leucovorin at a dose of 400 mg/m2 iv over two hours (day 1), Fluorouracil at a dose of 400 mg/m² iv bolus (day 1), and Fluorouracil at a dose of 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX
Description: Oxaliplatin at a dose of 85 mg/m² iv over two hours (day 1), Leucovorin at a dose of 400 mg/m2 iv over two hours (day 1), Fluorouracil at a dose of 400 mg/m² iv bolus (day 1), and Fluorouracil at a dose of 2400 mg/m² iv continuous infusion over 44 hours (day 1+2) every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLOT
Description: Docetaxel at a dose of 50 mg/m² iv over one hour (day 1), Oxaliplatin at a dose of 85 mg/m² iv over two hours (day 1), Leucovorin\* at a dose of 200 mg/m² iv over one hour (day 1), Fluorouracil at a dose of 2600 mg/m² iv over 24 hours (day 1) every 2 weeks~\* Note: Leucovorin can be replaced by sodium folinate that is given according to local guideline.
Study: NCT00617331

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subvirion inactivated influenza A/H9N2 (G9 variant) vaccine
Description: Inactivated subvirion influenza A/chicken/Hong Kong/G9/97 (H9N2) vaccine administered via intramuscular (IM) injection, dose 7.5 or 30 micrograms.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subvirion inactivated influenza A/H9N2 (G9 variant) vaccine
Description: Inactivated subvirion influenza A/chicken/Hong Kong/G9/97 (H9N2) vaccine administered via intramuscular (IM) injection, dose 7.5 or 30 micrograms.
Study: NCT03669913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lessons on comprehensive sexuality education
Description: Provision of 11 standardized lessons on comprehensive sexuality education based on international guidance on sexuality education by UNESCO
Study: NCT03036644

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: e-cigarette (PG+VG without nicotine; low temperature)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: e-cigarette (PG+VG without nicotine; low temperature)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: e-cigarette (PG+VG with nicotine; low temperature)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: e-cigarette (PG+VG without nicotine; high temperature)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: e-cigarette (PG+VG with nicotine; high temperature)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tobacco cigarette
Study: NCT00891332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 plus LV (The combination therapy of S-1 and Leucovorin)
Description: S-1 40-60 mg bid day 1～day 7 LV 25 mg bid day 1～day 7
Study: NCT00825630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole (Lanton)
Description: Oral administration of Lanzoprazole for 14 days in 25 patients with H.pylori infection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprezole (Losec)
Description: Oral administration of Omeprazole for 14 days in 25 patients with H.pylori infection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole(Controloc)
Description: Oral administration of Pantoprazole for 14 days in 25 patients with H.pylori infection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole (Nexium)
Description: Oral administration of Esomeprazole for 14 days in 25 patients with H.pylori infection
Study: NCT02998424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Continuous infusion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pupillary diameter measurement
Description: Instantaneous measure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pupillary diameter measurement
Description: Instantaneous measure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pupillary diameter measurement
Description: Instantaneous measure
Study: NCT01910857

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: weight reduction, low salt, physical activity, stress reduction
Study: NCT01765543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin at a dose of 600 mg as capsules orally once daily will be administered from Days 8 through 23 (Periods B and C).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Participants, after an overnight fast of at least 10 hours, will receive vemurafenib at a dose of 960 mg as film-coated tablets orally on Day 1 (Period A) and on Day 17 (Period C).
Study: NCT03895346

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness meditation is a technique of sustained attention and focus, involving preventing the mind from wandering from the meditative object (i.e. breath or body sensations)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain Games and Puzzles
Description: Intervention will include the instruction and practice of puzzles such as word searches, crossword puzzles, Sudoku, and KenKen.
Study: NCT04176497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-HBED-CC-PSMA
Description: Radioactive tracer used during imaging to help detect PSMA expressing tumor cells.
Study: NCT05338515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally.
Study: NCT00106938

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid artery endarterectomy (surgical)
Description: Carotid artery endarterectomy (surgical)
Study: NCT02586987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Selumetinib oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Selumetinib oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Selumetinib oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Selumetinib oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab, IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab, IV
Study: NCT01861938

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Melanoma vaccine modified to express HLA A2/4-1BB ligand
Study: NCT03093961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IASD implant
Description: Single arm for implant
Study: NCT04451161

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Attention Control
Description: Didactic presentation of implementation-related content (e.g., information about the importance of implementing, definitions of key terms, etc.) to control for facilitator, dose, information provided, and delivery platform
Study: NCT01124708

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TC-5619-238
Description: TC-5619-238 will be provided as white, opaque gelatin capsules in strengths of 1mg, 5mg, and 25mg (as free base). Subjects will take 1mg TC-5619, 5mg TC-5619, 25mg TC-5619, or matching placebo - one capsule once daily p.o.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be provided as white, opaque gelatin capsules in sham strengths of 1mg, 5mg, and 25mg
Study: NCT03911921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RSYRT decoction
Description: Compound granules of traditional Chinese medicine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astragalus membranaceus
Description: One herb
Study: NCT04102631

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: colonoscopy with assistance of Endo.Angel
Description: Patients in exposed group will receive colonoscopy with assistance of Endo.Angel,a real-time quality monitoring system based on computer vision,which is used to monitor the velocity of insertion of the endoscope, record the time of insertion and withdrawal of the endoscope, and remind endoscopists of the blind areas caused by intestinal segment slipping.

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: colonoscopy without assistance of Endo.Angel
Description: Patients in non-exposed group will receive colonoscopy without assistance of Endo.Angel.
Study: NCT00770692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone 1 mg- Elderly
Description: Elderly participants: Eszopiclone 1 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone 2 mg- Elderly
Description: Elderly participants: Eszopiclone 2 mg tablet and 1 tablet placebo 1 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone 3 mg- Non-elderly
Description: Non-elderly participants: Eszopiclone 3 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone 2 mg- Non-elderly
Description: Non-elderly participants: Eszopiclone 2 mg tablet and 1 tablet of placebo 3 mg daily by mouth at bedtime for 24 weeks.~Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment.
Study: NCT01742520

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: multiple doses of sucrose
Description: unlimited number of doses par day- current status in our NICU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formula or breast milk
Description: 1-3 minutes prior to every painful procedure, breast milk or formula 0.5-1 ml will be given on the anterior part of the tongue
Study: NCT01861236

Intervention type: DRUG
Intervention: Firmagon® (degarelix)
Description: Monthly subcutaneous injections
Study: NCT01908790

Intervention type: DEVICE
Intervention: Mespere Venous Oximeter
Description: The Mespere VA Oximeter System is a non-invasive medical device for measurement of venous blood oxygenation.

Intervention type: DEVICE
Intervention: Avoximeter 4000
Description: The portable Avoximeter 4000 provides rapid, accurate assessment of the patient's true oxygenation status at the bedside. Features: Results in less than 10 seconds; No sample preparation required; Uses whole blood sample; Easy to use.
Study: NCT04192123

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HM242
Description: HM242-Solution and HM242-Gel will be topically applied in an occlusive patch for 48h on healthy skin on the subject's outer part of the upper arm.
Study: NCT01123317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Subjects will be randomly assigned to either OT-Placebo or Placebo-OT order for PET scan drug administration and will receive the first of the two intranasal doses at Pet scan 1 and the second intranasal dose of the subsequent treatment at Pet Scan 2
Study: NCT01117766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Dose titration according to following regimen: 75mg BID for 3 days; 150mg for 4 days; 225mg BID for 4 days; 300mg BID for 17 days. Dose reduced for renally impaired patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID dosing for 28 days
Study: NCT02824471

Intervention type: OTHER
Intervention: SCD Group
Description: No Intervention. Use of discard blood/tissue

Intervention type: OTHER
Intervention: SCD Group
Description: No Intervention. Use of discard blood/tissue
Study: NCT01456091

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AIM 4 Teen Moms
Description: The AIM (Adult Identity Mentoring) 4 Teen Moms program is a combination of individual and small group sessions intervention that encourages parenting young women ages 15-19 years old to delay rapid repeat pregnancies for 24 months or later.
Study: NCT02593513

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Daifert

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control Group
Description: Control - Morphological Assessment
Study: NCT01817465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motilitone ®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoline®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Motilitone® and Pantoline®
Study: NCT03766490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Capsule, P.O. 12mg qd ,days 1-14, 21 days a cycle
Study: NCT02250248

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AttraX Putty

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Iliac Crest Bone Graft (ICBG)
Study: NCT03766490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Tablet, P.O. 250mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Tablet, P.O. 125mg tid
Study: NCT01744119

Intervention type: DEVICE
Intervention: Vascutek Anaconda™ Stent Graft System
Study: NCT03017118

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Turmeric
Description: Subjects will receive turmeric (100 mg pastille) 3 times per day for 6 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in the control group will receive a placebo 3 times per day for 6 weeks.
Study: NCT03398330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone Tamper Resistant
Description: Orally taking Oxycodone Tamper Resistant 40mg in fed state

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyContin®
Description: Orally taking OXYCONTIN® 40mg in fed state
Study: NCT03198871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen Injectable Product
Description: The interventional group will receive 1 gram intravenous acetaminophen at the start of wound closure to be repeated every 6 hours for 48 hours postoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%, Intravenous
Description: The placebo group will be given an intravenous placebo of saline solution at wound closure and repeated every 6 hours for 48 hours postoperatively.
Study: NCT04462289

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive Outreach
Description: Motivational electronic offer of tobacco cessation support via motivational texting program with care connection to patient's choice of smoking cessation programs
Study: NCT01499537

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: biliary drainage
Description: percutaneous transhepatic biliary drainage (PTBD)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS guided biliary drainage
Description: endoscopic ultrasonography guided biliary drainage through the duodenal or the gastric wall
Study: NCT02930148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEGASO System (ICT based system/mHealth solution)
Description: Participants will be provided with a smart phone with the PEGASO system and will be asked to join the PEGASO community through the PEGASO Portal. Two smart garments, and two sensors will be provided at month 2 (to minimise the burden on the schools and participants allocating time and resources). The PEGASO System allows empowering the participants toward healthy habits, recording what he or she eats, monitor physical activity variables. The serious game is a central motivational component of PEGASO: it has an energy bar, used up by the player's actions, and replenished when achieving their behavioural goals, and it implements research mechanics that require the player to apply and develop their nutritional knowledge. The Bridge allows the connection between the PEGASO ecosystem and the personal health folder by creating a report to be shared with physicians
Study: NCT01130792

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG
Description: 10 Billion Organisms Given Mixed In Milk As Food Supplement Once Daily For Four Weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Inulin
Description: Identical appearing capsules containing a powder resembling the LGG to be given as for intervention
Study: NCT02462226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The-Optimal-Lymph-Flow
Description: The-Optimal-Lymph-Flow ™ is a web-based educational and behavioral program focusing on self-care strategies to manage pain and symptoms related to lymphedema. The Optimal Lymph-Flow™ is the only evidence-based self-care program designed to effectively help women treated for breast cancer manage daily pain and symptoms related to lymphedema. Grounded in research-driven behavioral strategies, the program is premised on empowering, rather than inhibiting, how breast cancer survivors live their lives. It emphasizes what to do, rather than what to avoid. It features a safe, feasible and easily-integrated-into-daily-routine of exercises to promote lymph flow and drainage, as well as guidance to maintain an optimal BMI.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Arm Precaution
Description: The webpage also has a section entitled Arm Precautions, representing current patient education that emphasizes precautionary lifestyle behaviors, such as avoidance of repetitive limb movement, lifting weighted objects, needle punctures, blood draw, and the use of compression garments for air travel in the affected limb.
Study: NCT02522468

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radioactive Seed Localization
Study: NCT03481348

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pharyngeal Electrical Stimulation
Description: Pharyngeal Electrical Stimulation is applied at the pharynx via a nasogastral tube for 10 minutes per day on 3 consecutive days.
Study: NCT02638909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceritinib
Description: Treatment with ceritinib will continue until patient experiences unacceptable toxicity that precludes further treatment, discontinues treatment at the discretion of the investigator or patient, starts a new anticancer therapy and/or dies.